恩替卡韦治疗乙型肝炎肝硬化效果的临床研究

目的研究恩替卡韦治疗乙型肝炎肝硬化的临床效果。方法选取2012年4月—2013年4月该院收治的100例乙型肝炎肝硬化患者,随机等分为对照组与观察组。对照组在常规治疗的基础上加用拉米夫定,观察组在常规治疗的基础上加用恩替卡韦,比较两组患者治疗前后肝功能指标（ALT、AST、TBIL、ALB）及肝纤维化指标（HA、LN、IV-C）变化情况。结果观察组肝功能指标（ALT、AST、TBIL、ALB）均有改善,治疗后ALT平均水平（50.12±14.45）U/L,AST平均水平（45.32±12.26）U/L,TBIL平均水平（21.48±5.74）umol/L,ALB平均水平（37.86±3.93）g/L,较对照组差异有统计学意义（P〈0.05）;观察组肝纤维化指标（HA、LN、IV-C）均有改善,治疗后HA平均水平（15.48±3.46）ng/L,LN平均水平（56.92±14.05）ng/L,IV-C平均水平（83.56±27.38）,较对照组差异有统计学意义（P〈0.05）。结论恩替卡韦治疗乙型肝炎肝硬化有助于改善患者肝功能及肝纤维化,临床上值得推广。

Clinical Study of the Effect of Entecavir Treatment on Hepatitis B Cirrhosis

Objective To study the clinical effect of entecavir in the treatment of hepatitis B cirrhosis. Methods 100 cases with hepatitis B cirrhosis admitted in our hospital from April 2012 to April 2013 were randomly and equally divided into the control group and the observation group. Based on the conventional treatment, the control group was treated by lamivudine, and the obser-vation group was treated by entecavir. The changes of liver function indexes（ALT, AST, TBIL, ALB） and liver fibrosis indexes（HA,LN, IV-C） were compared between the two groups before and after treatment. Results The liver function indexes（ALT,AST,TBIL,ALB） of the observation group were improved, after treatment, the average level of ALT was（50.12 ±14.45） U/L, and that of AST was（45.32±12.26） U/L, that of TBIL was（21.48±5.74） umol/L, that of ALB was（37.86±3.93） g/L, compared with that of the control group, respectively, the differences between the groups were statistically significant（P〈0.05）; the liver fibrosis indexes（HA, LN, IVC） were improved, after treatment, the average level of HA was（15.48 ±3.46） ng/L, and that of LN was（56.92±14.05） ng/L, that of IV-C was（83.56±27.38）, compared with that of the control group, respectively, the differences between the groups were statistically significant（P〈0.05）. Conclusion Entecavir for the treatment of hepatitis B cirrhosis is helpful to improve the liver function and liver fibrosis of the patients, which is worth promoting clinically.